5-Jul-2011 - Infants of human immunodeficiency virus 1 (HIV-1) infected mothers who were treated before and after
birth with the protease inhibitor lopinavir-ritonavir were more likely to experience adrenal dysfunction, including life-threatening
adrenal insufficiency in premature infants, compared with a zidovudine-based regimen, according to a preliminary report in the July
6 issue of JAMA .
"The HIV-l transmission rate to newborns is now less than 1 percent for women treated during pregnancy. For pregnant women not
optimally treated, as in cases of HIV diagnosis late during pregnancy or persistent viral replication at delivery, several guidelines,
observational reports, and the results of a recent controlled study suggest reinforcing the postnatal phase of treatment with a
combination of anti-retrovirals, as a 'postexposure prophylaxis.' The protease inhibitor lopinavir, with its pharmacological
booster ritonavir (lopinavir-ritonavir), is now the ritonavir-boosted protease inhibitor most widely prescribed in
children," according to background information in the article.
Lopinavir-ritonavir is licensed in the United States for HIV-infected newborns older than 14 days and in Europe for children older
than 2 years. However, published data concerning its use in newborns are scarce. In April 2010, one of the centers of the French national
screening program for congenital adrenal hyperplasia (CAH; a group of inherited disorders of the adrenal glands) identified a transient
increase of 17-hydroxyprogesterone (17OHP; a steroid hormone produced mainly by the adrenal glands) in dried blood spots from 2
children treated at birth with lopinavir-ritonavir.
Albane Simon, M.D., of the Hopital Necker-Enfants Maiades, Assistance Publique-Hopitaux de Paris, France, and colleagues conducted
a study to assess whether immediate postnatal exposure to lopinavir-ritonavir was associated with changes in adrenal function compared
with standard prophylactic zidovudine treatment. The study included information from the database of the national screening for
congenital adrenal hyperplasia and the French Perinatal Cohort, with a comparison of HIV-1-uninfected newborns postnatally
treated with lopinavir-ritonavir and controls treated with standard zidovudine. There was an assessment of levels of
17OHP and dehydroepiandrosterone-sulfate (DHEA-S; the circulating form of a steroid produced primarily by the
adrenal cortex) concentrations during the first week of treatment.
Among mother-child pairs in the Paris area enrolled in the study cohort between December 2004 and September 2008, the authors
evaluated 50 HIV-1 uninfected children who received lopinavir-ritonavir just after birth, and 108 who received standard prophylaxis:
zidovudine alone (n= 100), zidovudine and lamivudine (n = 6), or zidovudine and nevirapine (n = 2). Among the 50 newborns treated
with lopinavir-ritonavir, 7 (14 percent) had abnormally high 17OHP results from dried blood spots (greater than 16.5 ng/mL at
term or greater than 23.1 ng/mL preterm) vs. 0 of 108 controls. For children born at term, 5 of 42 newborns treated with
lopinavir-ritonavir vs. 0 of 93 controls had values greater than 16.5 ng/mL.
The median (midpoint) 17OHP value for term newborns treated with lopinavir-ritonavir was 9.9 ng/mL vs. 3.7 ng/mL in controls.
The difference observed in median 17OHP values between treated newborns and controls was higher in children also exposed in utero
(11.5 ng/mL vs. 3.7 ng/mL) than not exposed in utero (6.9 ng/mL vs. 3.3 ng/mL). The median DHEA-S values for children born at
term were 9,242 ng/mL for the treated group vs. 484 ng/mL for the controls. Consistent with the findings for 17OHP, the
DHEA-S values were significantly higher only in cases also exposed in utero to ritonavir-boosted protease inhibitor.
"All term newborns treated with lopinavir-ritonavir were asymptomatic, although 3 premature newborns experienced life-threatening
symptoms compatible with adrenal insufficiency, including hyponatremia (abnormally low level of sodium in the blood) and hyperkalemia,
(higher than normal levels of potassium in the circulating blood; associated with kidney failure) with in 1 case, cardiogenic shock.
All symptoms resolved following completion of the lopinavir-ritonavir treatment," the authors write.
"In summary, our findings of the association between lopinavir-ritonavir and transient adrenal dysfunction in HIV-1 uninfected
newborns suggest that lopinavir-ritonavir and more generally ritonavir boosting should be used with caution, if at all, in premature
infants, and if this drug regimen is administered to full-term infants, it should be used under electrolyte monitoring. Whether
more prolonged exposure of HIV-1 -infected or uninfected infants via breast milk is associated with endocrine disruption
should be carefully investigated, and the apparent risk associated with prenatal ritonavir exposure also merits further evaluation."
( JAMA . 2011;30670-78. Available pre-embargo to the media at www.jamamedia.org )
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
To contact corresponding author Stephane Blanche, M.D., email firstname.lastname@example.org .